Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity.

Prostaglandins, leukotrienes, and essential fatty acids·2006
Same author

Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCT.

Bone·2005
Same author

Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins.

Cell death and differentiation·2004
Same author

M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.

Cell death and differentiation·2003
Same author

Preclinical safety profile of alendronate.

International journal of clinical practice. Supplement·2003
Same author

Preclinical evidence of normal bone with alendronate.

International journal of clinical practice. Supplement·2003
Same journal

Risk of Femoral Head Osteonecrosis Following Hip Trauma in Adults With Systemic Lupus Erythematosus.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study: Erratum.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study: Erratum.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Microbiome Dysbiosis as a Potential Driver of Inflammatory Mimicry in Pachydermoperiostosis-associated Hypertrophic Osteoarthropathy.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Understanding Gaps in Methotrexate Education in the Adolescent and Young Adult Population.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Prevalence of Attention Deficit Hyperactivity Disorder in Adult Patients With Fibromyalgia.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

Alendronate: preclinical studies.

G A Rodan1

  • 1Department of Bone Biology and Osteoporosis Research, Merck Research Laboratories, West Point, Pennsylvania.

Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

Alendronate effectively treats osteoporosis by preventing bone loss and enhancing bone mass and strength in animal models. This aminobisphosphonate works by inhibiting bone resorption and osteoclast activity, ensuring normal bone quality.

Related Experiment Videos

Last Updated: Jun 27, 2026

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

Area of Science:

  • Pharmacology
  • Orthopedics
  • Bone Biology

Background:

  • Osteoporosis is a prevalent condition characterized by bone loss.
  • Estrogen deficiency significantly contributes to osteoporosis development.
  • Alendronate is a recently approved aminobisphosphonate for osteoporosis treatment.

Purpose of the Study:

  • To evaluate the efficacy of alendronate in established animal models of osteoporosis.
  • To assess the long-term effects of alendronate on bone quality and strength.

Main Methods:

  • Studies were conducted in ovariectomized rats and baboons to model osteoporosis.
  • Histomorphometric and biomechanical analyses were performed in rats, dogs, pigs, and primates.
  • Alendronate was administered at multiples of the human dose for up to 3 years.

Main Results:

  • Alendronate significantly prevented bone loss and increased bone mass and strength compared to estrogen-deficient controls.
  • Long-term treatment with alendronate maintained normal bone quality in multiple species.
  • Alendronate demonstrated inhibition of bone resorption and turnover at tissue and cellular levels, targeting osteoclast activity.

Conclusions:

  • Alendronate is a highly effective therapeutic agent for osteoporosis.
  • The drug demonstrates a favorable long-term safety profile regarding bone quality.
  • Alendronate's mechanism of action involves suppressing bone resorption and osteoclast function.